Literature DB >> 16279764

7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine: a functionally selective gamma-aminobutyric acid(A) (GABA(A)) alpha2/alpha3-subtype selective agonist that exhibits potent anxiolytic activity but is not sedating in animal models.

Robert W Carling1, Andrew Madin, Alec Guiblin, Michael G N Russell, Kevin W Moore, Andrew Mitchinson, Bindi Sohal, Andrew Pike, Susan M Cook, Ian C Ragan, Ruth M McKernan, Kathleen Quirk, Pushpinder Ferris, George Marshall, Sally Ann Thompson, Keith A Wafford, Gerard R Dawson, John R Atack, Timothy Harrison, José L Castro, Leslie J Street.   

Abstract

There is increasing evidence that compounds with selectivity for gamma-aminobutyric acid(A) (GABA(A)) alpha2- and/or alpha3-subtypes may retain the desirable anxiolytic activity of nonselective benzodiazepines but possess an improved side effect profile. Herein we describe a novel series of GABA(A) alpha2/alpha3 subtype-selective agonists leading to the identification of the development candidate 17, a nonsedating anxiolytic in preclinical animal assays.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16279764     DOI: 10.1021/jm058034a

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

Review 1.  Use of multicomponent reactions in developing small-molecule tools to study GABAA receptor mechanism and function.

Authors:  Ryan W Lewis; George P Hess; Bruce Ganem
Journal:  Future Med Chem       Date:  2011-02       Impact factor: 3.808

2.  Reducing abuse liability of GABAA/benzodiazepine ligands via selective partial agonist efficacy at alpha1 and alpha2/3 subtypes.

Authors:  Nancy A Ator; John R Atack; Richard J Hargreaves; H Donald Burns; Gerard R Dawson
Journal:  J Pharmacol Exp Ther       Date:  2009-09-29       Impact factor: 4.030

Review 3.  GABA(A) receptor subtype-selective efficacy: TPA023, an alpha2/alpha3 selective non-sedating anxiolytic and alpha5IA, an alpha5 selective cognition enhancer.

Authors:  John R Atack
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

4.  Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors.

Authors:  Amanda P Skoumbourdis; Christopher A Leclair; Eduard Stefan; Adrian G Turjanski; William Maguire; Steven A Titus; Ruili Huang; Douglas S Auld; James Inglese; Christopher P Austin; Stephen W Michnick; Menghang Xia; Craig J Thomas
Journal:  Bioorg Med Chem Lett       Date:  2009-01-23       Impact factor: 2.823

5.  GABA(A) receptor α subunits differentially contribute to diazepam tolerance after chronic treatment.

Authors:  Christiaan H Vinkers; Ruud van Oorschot; Elsebet Ø Nielsen; James M Cook; Henrik H Hansen; Lucianne Groenink; Berend Olivier; Naheed R Mirza
Journal:  PLoS One       Date:  2012-08-13       Impact factor: 3.240

6.  Pharmacological Properties of DOV 315,090, an ocinaplon metabolite.

Authors:  Dmytro Berezhnoy; Maria C Gravielle; Scott Downing; Emmanuel Kostakis; Anthony S Basile; Phil Skolnick; Terrell T Gibbs; David H Farb
Journal:  BMC Pharmacol       Date:  2008-06-13

Review 7.  Allosteric GABAA Receptor Modulators-A Review on the Most Recent Heterocyclic Chemotypes and Their Synthetic Accessibility.

Authors:  Blanca Angelica Vega Alanis; Maria Teresa Iorio; Luca L Silva; Konstantina Bampali; Margot Ernst; Michael Schnürch; Marko D Mihovilovic
Journal:  Molecules       Date:  2020-02-24       Impact factor: 4.927

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.